Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
Rhea-AI Summary
Biomea Fusion (BMEA) has announced a conference call and webcast scheduled for Tuesday, December 17, 2024, at 8:00 am EST to present topline results from COVALENT-111, their Phase II trial of icovamenib in patients with type 2 diabetes. The company, which focuses on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, will make the webcast available to registered attendees through their investor relations website, with a replay available afterward.
Positive
- None.
Negative
- None.
News Market Reaction – BMEA
On the day this news was published, BMEA declined 20.68%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Tuesday, December 17, 2024 at 8:00 am EST
REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company’s Phase II trial of icovamenib in patients with type 2 diabetes.
Conference Call and Webcast Details
Webcast of Biomea’s investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to registered attendees under the Investors and Media section of the company’s website at https://investors.biomeafusion.com/news-events/events. A replay of the presentation will be archived on Biomea’s site following the event.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Ramses Erdtmann
COO & President of Biomea Fusion
re@biomeafusion.com
FAQ
When will Biomea Fusion (BMEA) announce COVALENT-111 Phase II trial results?
What is the purpose of Biomea's COVALENT-111 Phase II trial?
How can investors access Biomea's (BMEA) COVALENT-111 trial results webcast?
What therapeutic areas does Biomea Fusion (BMEA) focus on?
